How Surbhi Sarna Built A $275M Biotech Company From Nothing

Founder Background & Motivation

• Serby Serna founded Envision Medical after a high-school health scare involving complex ovarian cysts where standard diagnostics (ultrasound and blood tests) could not determine if the mass was cancerous.
• She aimed to prevent invasive surgeries and fertility loss by developing a device for the early detection of ovarian cancer, a goal formalized in her high school personal statement.
• Serna launched Envision at age 24 without a PhD, MD, or MBA, facing initial feelings of inadequacy against typical biotech founder profiles.

Product Development & Technical Milestones

• The company developed the first and only device cleared to collect cells directly from the fallopian tube to evaluate malignant features in complex cysts.
• The device underwent prototype stages, multiple clinical studies, and secured FDA clearance before its sale.
• Serna validated the concept by cold-calling a gynecologist under the guise of a patient, eventually leveraging that connection to introduce the technology to physicians at UC Davis and Stanford.

Fundraising Challenges & Investor Bias

• Serna rejected by approximately 50 investors during the initial seed round, citing her demographic (brown woman without advanced degrees) and lack of prior progress.
• Early investors dismissed women's health as an insufficient market size or labeled it "bikini medicine," despite the sector affecting 50% of the population.
• Seed funding was ultimately secured by two female investors who committed on the condition Serna could find one additional co-investor.

Capital & Operational Scale

• Following the seed round, Envision raised an additional $20 million in venture capital.
• The company assembled a world-class team to advance the technology through clinical trials and regulatory approval.

Exit Event & Financial Outcome

• Boston Scientific initiated acquisition talks after reviewing Envision's clinical data, ultimately offering to purchase the company for $275 million.
• Serna, who initially had no interest in an acquisition, signed the deal with her family present, citing the need to secure the product's future and impact women's health.

Current Role & Forward-Looking Statements

• Serna transitioned to a Group Partner role at Y Combinator, focusing on healthcare and biotech founders.
• She advocates for evaluating founders based on problem-solution fit and conviction rather than academic credentials like MDs or PhDs.
• Her stated goal is to accelerate market entry for technologies addressing critical needs in agriculture, food safety, and cancer detection.